<DOC>
	<DOCNO>NCT00001538</DOCNO>
	<brief_summary>This randomize , double blind study safety immunogenicity APL 400-003 , plasmid DNA vaccine encode env rev gene HIV-1 , HIV-negative volunteer . Three dos vaccine test : 100 , 300 , 1000 micro g. 8 volunteer per dose randomize : 6 plasmid vaccine , 2 vehicle control . Immunizations administer day 0 week 4 8 , booster immunization administer week 24 . An additional 5 volunteer may include open manner dose likely used subsequent study . The primary aim study determine : 1. safety APL 400-003 , evaluate clinical laboratory safety parameter 2. immunogenicity APL 400-003 , determine broad range laboratory assay . Up 33 patient ( allow drop-outs ) enrol study , volunteer follow one year immunization .</brief_summary>
	<brief_title>Phase I Study APL 400-003 , Candidate HIV Vaccine , HIV-Negative Volunteers</brief_title>
	<detailed_description>This randomize , double blind study safety immunogenicity APL 400-003 , plasmid DNA vaccine encode env rev gene HIV-1 , HIV-negative volunteer . Four dos vaccine test : 100 , 300 , 1000 , 3000 microgram . 8 volunteer per dose randomize : 6 plasmid vaccine , 2 vehicle control . Immunizations administer day 0 week 4 8 , booster immunization administer week 24 . An additional 5 volunteer may include open manner dose likely used subsequent study . The primary aim study determine : 1. safety APL 400-003 , evaluate clinical laboratory safety parameter 2. immunogenicity APL 400-003 , determine broad range laboratory assay . Up 41 patient ( allow drop-outs ) enrol study , volunteer follow one year immunization .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 60 year age , HIV1 negative HIV1 ELISA , HIV PCR Western Blot analysis . Subjects good health evidence underlie disease base history , physical exam laboratory analysis . Must normal organ function characterize following : Hematopoietic : absolute granulocyte count least 1500/mm ( 3 ) ; platelet count least 150 , 000/mm ( 3 ) ; hematocrit within normal range . Renal : BUN le 23 mg/dl ; creatine le 1.6 mg/dl . Hepatic : serum total bilirubin le 1.5 mg % . Metabolic : ALT le equal 1.5 x upper limit normal range ; serum calcium within normal range ; serum lactate within normal range ; total serum CPK within normal range . Endocrine : serum glucose within normal range . Immunologic : CD4 count great equal 500 cells/mm ( 3 ) ; total serum immunoglobulin ( IgM , IgG IgA ) level within normal range . No clinically significant laboratory abnormality . All subject must understand basis transmission HIV common sexual blood borne infection agree practice abstinence clinically accept method prevention , include barrier protection intercourse duration study . Female subject child bear potential must negative pregnancy test . Must available active followup . Able give inform consent sign Institutional Review Board ( IRB ) approve consent form ( ) . Must previous immunization experimental vaccine direct HIV receipt experimental agent within 30 day prior enrollment . Must receive blood product immunoglobulin within 6 month prior enrollment . Must expose potentially infective HIV fluid within prior 6 month test positive HIV time . No history prior disease therapy would affect immune function include : Prior malignancy , except curativelytreated basal cell squamous cell carcinoma skin carcinoma situ cervix ; Radiation therapy cytotoxic/cancer chemotherapy ; immunodeficiency autoimmune disease ; Acute infection recent ( within 6 month ) history chronic infection . Female subject must nurse child . Must take medication may affect immune function , follow exception : subject may take low dos nonprescription strength NSAIDS ( e.g . ibuprofen aspirin ) acetaminophen . No known hypersensitivity bupivacaine amidetype local anesthetic ( lidocaine , dibucaine , mepivacaine , prilocaine ) history anaphylaxis serious adverse reaction vaccine . No evidence active drug alcohol abuse uncontrolled ( unstable ) psychiatric disorder would interfere study participation . Must engage HIVrelated highrisk behavior unprotected sex , sex multiple partner , intravenous drug use . No evidence infection HBV , HIV1 , HCV HTLV1 use standard testing procedure . Must positive result antiDNA antibody measure standard testing procedure ( antiDNA antibody antinuclear antibody ( ANA ) assay . This study permit enrollment volunteer low positive ANA ( less equal 1:160 ) titer , clinical evidence underlie disorder associate positive ANA , first degree relative autoimmune disease , antiDNA ENA negative .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2000</verification_date>
	<keyword>AIDS</keyword>
	<keyword>DNA Vaccine</keyword>
	<keyword>Naked DNA</keyword>
	<keyword>Plasmid</keyword>
	<keyword>gp 160</keyword>
</DOC>